Clinical trials: Biliary Tract Cancer (BTC)
Biliary Tract Cancer (BTC)
The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer
Recent progress in comprehensive genomic profiling for advanced BTC has helped to clarify tumorigenesis and facilitate the coming era of precision medicine.
- Trial name
- NCT05036486
- Testing
- next-generation sequencing
- Where
- 13 sites in Taiwan
- Volunteers
- 480 people
- Sponsor
- National Health Research Institutes, Taiwan
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Biliary Tract Cancer
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
FOLFIRI as a salvage treatment in metastatic biliary tract cancer (BTC) patients who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110510
- Testing
- Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Biliary Tract Neoplasms
The Effect of Individualized Precision Therapy Programs in Patients With BTC
This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected.
- Trial name
- NCT02943031
- Testing
- Individualized Precision Therapy Programs
- Where
- China
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).
- Trial name
- HP-BTC-001 (NCT05742750)
- Testing
- Camrelizumab and Apatinib Plus GP
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sun Yat-sen University
Biliary Tract Cancer, Cholangiocarcinoma
SHR-1210 in Combination With GEMOX in Patients With Advanced BTC
This is a single-arm, open-label and exploratory clinical study of PD-1 monoclonal antibody SHR-1210 combined with GEMOX regimen (gemcitabine combined oxaliplatin) in the treatment of advanced biliary malignancies.
- Trial name
- NCT03486678
- Testing
- SHR-1210+GEMOX
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Biliary Tract Cancer (BTC)
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
According to current clinical guidelines, first-line treatment for advanced biliary tract cancer (BTC) is the gemcitabine plus cisplatin (GC) regimen combined with immunotherapy, which has been shown to improve patient outcomes.
- Trial name
- NCT07638501
- Testing
- Sintilimab + GC, SBRT 7Gy✖️5 QD
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Biliary Tract Cancer
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-016 (NCT06653127)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
Biliary Tract Cancer
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
This research is studying the effect of the combination of how two study drugs (Nivolumab and DKN-01) works in people with advanced biliary tract cancer.
- Trial name
- NCT04057365
- Testing
- Nivolumab, DKN-01
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Biliary Tract Cancer (BTC)
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of Iparomlimab and Toripalimab (QL1706) in combination with bevacizumab and chemotherapy as first-line treatment for patients with…
- Trial name
- NCT07619235
- Testing
- Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xianglin Yuan
Biliary Tract Cancers
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator's choice of 3 different gemcitabine-based chemotherapy regimens in participants with…
- Trial name
- TopDouble (NCT05924880)
- Testing
- durvalumab
- Where
- 19 sites in China
- Volunteers
- 116 people
- Sponsor
- AstraZeneca